{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:13:38Z","timestamp":1776474818725,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become available. Prophylactic dosing of EHL-FIX concentrates can be optimized by assessment of individual pharmacokinetic (PK) parameters. To determine these parameters, limited sampling strategies (LSSs) may be applied. The study aims to establish adequate LSSs for estimating individual PK parameters of EHL-FIX concentrates using <jats:italic>in silico<\/jats:italic> evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Monte Carlo simulations were performed to obtain FIX activity versus time profiles using published population PK models for N9-GP (Refixia), rFIXFc (Alprolix), and rIX-FP (Idelvion). Fourteen LSSs, containing three or four samples taken within 8\u00a0days after administration, were formulated. Bayesian analysis was applied to obtain estimates for clearance (CL), half-life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>), time to 1% (Time<jats:sub>1%<\/jats:sub>), and calculated weekly dose (Dose<jats:sub>1%<\/jats:sub>). Bias and precision of these estimates were assessed to determine which LSS was adequate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For all PK parameters of N9-GP, rFIXFc and rIX-FP bias was generally acceptable (range:\u2009\u22125% to 5%). For N9-GP, precision of all parameters for all LSSs was acceptable (&lt;\u200925%). For rFIXFc, precision was acceptable for CL and Time<jats:sub>1%<\/jats:sub>, except for <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> (range: 27.1% to 44.7%) and Dose<jats:sub>1%<\/jats:sub> (range: 12% to 29.4%). For rIX-FP, all LSSs showed acceptable bias and precision, except for Dose<jats:sub>1%<\/jats:sub> using LSS with the last sample taken on day 3 (LSS 6 and 10).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Best performing LSSs were LSS with samples taken at days 1, 5, 7, and 8 (N9-GP and rFIXFc) and at days 1, 4, 6, and 8 (rIX-FP), respectively.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03173-2","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:41:59Z","timestamp":1634280119000},"page":"237-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-0358","authenticated-orcid":false,"given":"T.","family":"Preijers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. W. F.","family":"van Spengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. W. G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"3173_CR1","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR et al (2014) Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 12:1935\u20131939. https:\/\/doi.org\/10.1111\/jth.12672","journal-title":"J Thromb Haemost"},{"key":"3173_CR2","doi-asserted-by":"crossref","unstructured":"Fijnvandraat K, Cnossen MH, Leebeek FWG, Peters M (2012) Diagnosis and management of haemophilia. BMJ 344:e2707","DOI":"10.1136\/bmj.e2707"},{"key":"3173_CR3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PHB Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs PHB, Pasi KJ (2003) Haemophilias A and B. Lancet Lond Engl 361:1801\u20131809. https:\/\/doi.org\/10.1016\/S0140-6736(03)13405-8","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"3173_CR4","first-page":"107","volume":"7","author":"FWG Leebeek","year":"2010","unstructured":"Leebeek FWG, Mauser-Bunschoten EP (2010) Nieuwe richtlijn diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Ned Tijdschr Hematol 7(3):107\u2013114","journal-title":"Ned Tijdschr Hematol"},{"key":"3173_CR5","unstructured":"Morfini M, Coppola A, Franchini M, Di Minno G (2013) Clinical use of factor VIII and factor IX concentrates. Blood Transfus 11:s55"},{"key":"3173_CR6","unstructured":"Novo Nordisk (2017) Refixia\u202f: EPAR - Product Information"},{"key":"3173_CR7","unstructured":"Swedish Orphan Biovitrum AB (2017) Alprolix\u202f: EPAR - Product Information"},{"key":"3173_CR8","unstructured":"CSL Behring (2018) Idelvion\u202f: EPAR - Product Information"},{"key":"3173_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/JBM.S81520","volume":"7","author":"M Nazeef","year":"2016","unstructured":"Nazeef M, Sheehan JP (2016) New developments in the management of moderate-to-severe hemophilia B. J Blood Med 7:27\u201338. https:\/\/doi.org\/10.2147\/JBM.S81520","journal-title":"J Blood Med"},{"key":"3173_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/jth.14153","volume":"16","author":"MV Ragni","year":"2018","unstructured":"Ragni MV, Croteau SE, Morfini M et al (2018) Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost 16:1437\u20131441. https:\/\/doi.org\/10.1111\/jth.14153","journal-title":"J Thromb Haemost"},{"key":"3173_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13013","volume":"22","author":"P Collins","year":"2016","unstructured":"Collins P, Chalmers E, Chowdary P et al (2016) The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemoph Off J World Fed Hemoph 22:487\u2013498. https:\/\/doi.org\/10.1111\/hae.13013","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"Suppl 4","key":"3173_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/hae.12405","volume":"20","author":"M Carcao","year":"2014","unstructured":"Carcao M (2014) Changing paradigm of prophylaxis with longer acting factor concentrates. Haemoph Off J World Fed Hemoph 20(Suppl 4):99\u2013105. https:\/\/doi.org\/10.1111\/hae.12405","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"3173_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hae.13970","volume":"26","author":"Y Brennan","year":"2020","unstructured":"Brennan Y, Parikh S, McRae S, Tran H (2020) The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation. Haemoph Off J World Fed Hemoph 26:529\u2013535. https:\/\/doi.org\/10.1111\/hae.13970","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"3173_CR14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jth.12000","volume":"10","author":"PW Collins","year":"2012","unstructured":"Collins PW, M\u00f8ss J, Knobe K et al (2012) Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost JTH 10:2305\u20132312. https:\/\/doi.org\/10.1111\/jth.12000","journal-title":"J Thromb Haemost JTH"},{"key":"3173_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40262-013-0129-7","volume":"53","author":"L Diao","year":"2014","unstructured":"Diao L, Li S, Ludden T et al (2014) Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet 53:467\u2013477. https:\/\/doi.org\/10.1007\/s40262-013-0129-7","journal-title":"Clin Pharmacokinet"},{"key":"3173_CR16","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/jth.13444","volume":"14","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Roberts J, Bensen-Kennedy D et al (2016) Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. J Thromb Haemost JTH 14:2132\u20132140. https:\/\/doi.org\/10.1111\/jth.13444","journal-title":"J Thromb Haemost JTH"},{"key":"3173_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/asheducation-2017.1.595","volume":"2017","author":"A Iorio","year":"2017","unstructured":"Iorio A (2017) Using pharmacokinetics to individualize hemophilia therapy. Hematol Am Soc Hematol Educ Program 2017:595\u2013604. https:\/\/doi.org\/10.1182\/asheducation-2017.1.595","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3173_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1055\/s-0038-1623531","volume":"118","author":"T Preijers","year":"2018","unstructured":"Preijers T, van Moort I, Fijnvandraat K et al (2018) Cross-evaluation of pharmacokinetic-guided dosing tools for factor VIII. Thromb Haemost 118:514\u2013525. https:\/\/doi.org\/10.1055\/s-0038-1623531","journal-title":"Thromb Haemost"},{"key":"3173_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/hae.12277","volume":"19","author":"E Berntorp","year":"2013","unstructured":"Berntorp E (2013) Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study. Haemoph Off J World Fed Hemoph 19:805\u2013807. https:\/\/doi.org\/10.1111\/hae.12277","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"3173_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/jth.13771","volume":"15","author":"T Preijers","year":"2017","unstructured":"Preijers T, Hazendonk HCAM, Fijnvandraat K et al (2017) In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. J Thromb Haemost 15:1737\u20131746. https:\/\/doi.org\/10.1111\/jth.13771","journal-title":"J Thromb Haemost JTH"},{"key":"3173_CR21","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2016","unstructured":"R Core Team (2017) R: a language and environment for statistical computing. Austria, Vienna"},{"key":"3173_CR22","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (eds) NONMEM 7.3 users guides. (1989\u20132011). Available via: https:\/\/nonmem.iconplc.com\/nonmem730\/nm730.pdf"},{"key":"3173_CR23","unstructured":"Dubois A, Bertrand J, Mentr\u00e9 F (2011) Mathematical expressions of the pharmacokinetic and pharmacodynamic models implemented in the PFIM software"},{"key":"3173_CR24","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/jth.12421","volume":"11","author":"D Feng","year":"2013","unstructured":"Feng D, Stafford KA, Broze GJ, Stafford DW (2013) Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost JTH 11:2176\u20132178. https:\/\/doi.org\/10.1111\/jth.12421","journal-title":"J Thromb Haemost JTH"},{"key":"3173_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12959-016-0104-2","volume":"14","author":"DW Stafford","year":"2016","unstructured":"Stafford DW (2016) Extravascular FIX and coagulation. Thromb J 14:35. https:\/\/doi.org\/10.1186\/s12959-016-0104-2","journal-title":"Thromb J"},{"key":"3173_CR26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.13360","volume":"169","author":"AJ Mahdi","year":"2015","unstructured":"Mahdi AJ, Obaji SG, Collins PW (2015) Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 169:768\u2013776. https:\/\/doi.org\/10.1111\/bjh.13360","journal-title":"Br J Haematol"},{"issue":"Suppl 5","key":"3173_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/hae.13028","volume":"22","author":"G Young","year":"2016","unstructured":"Young G, Mahlangu JN (2016) Extended half-life clotting factor concentrates: results from published clinical trials. Haemoph Off J World Fed Hemoph 22(Suppl 5):25\u201330. https:\/\/doi.org\/10.1111\/hae.13028","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"3173_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1365-2516.2001.00465.x","volume":"7","author":"S Bj\u00f6rkman","year":"2001","unstructured":"Bj\u00f6rkman S, Shapiro AD, Berntorp E (2001) Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemoph Off J World Fed Hemoph 7:133\u2013139","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"Suppl 4","key":"3173_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","volume":"18","author":"PW Collins","year":"2012","unstructured":"Collins PW (2012) Personalized prophylaxis. Haemoph Off J World Fed Hemoph 18(Suppl 4):131\u2013135. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02838.x","journal-title":"Haemoph Off J World Fed Hemoph"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03173-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:04:31Z","timestamp":1641801871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3173"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03173-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the Competing interest form and have no financial or personal relationships that could inappropriately influence the study. KM reports grants and other from Bayer, grants and other from Sanquin, grants from Pfizer, other from Boehringer Ingelheim, other from BMS, other from Aspen, other from Uniqure, outside the submitted work. KF1 reports grants from CSL Behring, grants from Novo Nordisk, other from Takeda, other from Roche, other from Pfizer, outside the submitted work. KF2 reports grants and other from Bayer, grants and other from Baxter\/Shire, grants and other from Novo Nordisk, other from Biotest, other from CSL Behring, other from Octapharma, grants and other from Pfizer, other from SOBI, other from Roche, outside the submitted work. FL an unrestricted research grant from CSL Behring, Shire\/Takeda, and Sobi; is a consultant for uniQure, Novo Nordisk, Biomarin, and Shire\/Takeda for performing the WiN study; is a consultant for uniQure, Novo Nordisk, and Shire\/Takeda, the fees of which go to the institution; and has received a travel grant from Sobi. He is also a DSMB member for a study by Roche. MC has received investigator-initiated research grants over the years from the Netherlands Organisation for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch \u201cInnovatiefonds Zorgverzekeraars,\u201d Baxter\/Baxalta\/Shire, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, and Nordic Pharma, and has served as a steering board member for Roche and Bayer. All grants, awards, and fees go to the Erasmus MC as institution. RM reports grants from Bayer, grants from Shire, grants from Merck Sharpe Dome, grants from CSL Behring, other from Bayer, other from Shire, outside the submitted work. Other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}